HCPCS code J3590: Unclassified biologics billing guide

Key Takeaways

HCPCS code J3590 covers unclassified biologics – physician-administered biological products with no specific HCPCS J-code on the date of service.

J3590 differs from J3490 by drug type: J3490 covers non-biological unclassified drugs, while J3590 is exclusively for biologics such as biosimilars and monoclonal antibodies.

Always bill J3590 alongside a matching CPT administration code (e.g., 96372 for injection, 96413 for chemotherapy infusion) or the claim will deny.

Pabau’s claims management software helps practices track prior authorizations, attach NDC numbers, and submit J3590 claims accurately without manual workarounds.

HCPCS code J3590 is the HCPCS Level II code for unclassified biologics – physician-administered biological products that have no specific HCPCS J-code on the date of service. It is always billed alongside a CPT administration code and requires the drug name, dosage, and NDC number on the claim.

This guide covers how HCPCS code J3590 works, when to use it versus related NOC codes, what documentation payers require, and how it fits into the wider medical billing process when denials occur.

HCPCS code J3590: Definition and clinical description

HCPCS code J3590 is the Level II code maintained by CMS for unclassified biologics. Its official descriptor is simply “Unclassified biologics,” and it belongs to the J-code range covering drugs administered by injection.

A biologic is defined as a medicinal preparation made from living organisms or their products, including serums, vaccines, antigens, antitoxins, biosimilars, and monoclonal antibodies. The code is “unclassified” for one reason: no specific HCPCS J-code exists for the product being administered on the date of service.

J3590 is a Not Otherwise Classified (NOC) code. NOC codes are intentionally broad. They exist so providers can bill for drugs that have received FDA approval or are otherwise payable but have not yet been assigned a permanent, product-specific HCPCS code. Once a dedicated code is established, J3590 should no longer be used for that drug.

Key code properties

J3590 vs J3490 vs C9399: Understanding the NOC code family

Three NOC codes cover unclassified drug and biologic billing. Choosing the wrong one is a common denial trigger, and payers do distinguish between them.

J3490 (Unclassified drugs)

J3490 covers unclassified drugs that are not biologics. Think small-molecule medications, traditional chemical compounds, or off-label drugs that lack a specific J-code. According to guidance addressed to NHIC Corp, the distinction is product type: if the administered drug is a biologic, use J3590. If it is a conventional drug, use J3490.

C9399 (New drug or biological, transitional)

C9399 is used within hospital outpatient settings under the Outpatient Prospective Payment System (OPPS). Per CMS coverage guidance, C-codes are assigned to new drugs and biologicals and generally expire or are replaced after approximately one year. Once a drug’s C-code lapses and no permanent code has been issued, the drug moves to J3590 for continued billing.

J9999 (Unclassified antineoplastic drugs)

J9999 is a separate NOC code specifically for antineoplastic (Cancer-fighting) drugs that lack a dedicated Q or J code. Once an antineoplastic receives its own code – as nivolumab did with HCPCS code J9299 – J9999 should no longer be used for it. The American Academy of Ophthalmology’s coding guidance for injectable drugs notes that NOC codes including J3490, J3590, and J7999 should only be reported when no valid specific HCPCS code describes the drug being administered. The same principle applies to J9999.

Drugs commonly billed under HCPCS code J3590

J3590 is a transitional placeholder. Any biologic that receives FDA approval but has not yet been assigned a permanent HCPCS J-code will be billed under J3590 until CMS issues a dedicated code. The list changes year to year as permanent codes are assigned or as new biologics enter the market.

Recent documented examples include the following biologics billed under J3590:

• Ublituximab-xiiy (Briumvi): Effective January 27, 2023, NC Medicaid covered this multiple sclerosis biologic under J3590 through the Physician Administered Drug Program (PADP).
• Eflapegrastim-xnst (Rolvedon): Covered under J3590 by NC Medicaid effective November 15, 2022, for subcutaneous use.
• Sutimlimab-jome (Enjaymo): Billed under J3590 per NC Medicaid billing guidelines as of May 2022.
• Rituximab-arrx (Riabni): Covered under J3590 effective January 5, 2021, for intravenous use.
• Bevacizumab (Avastin) off-label intravitreal use: Blue Cross Blue Shield of Michigan instructed providers in June 2024 to bill J3590 when Avastin is used for intravitreal treatment for commercial Blue Cross members.
• Aflibercept 8mg (Eylea HD): Temporarily billed under J3590 when a dedicated HCPCS code was first made available at the start of the year; permanent code now assigned.

Washington State’s Health Care Authority maintains a published list of drugs billed under miscellaneous HCPCS codes including J3490, J3590, J9999, and C9399 that require prior authorization. Checking your state Medicaid program’s equivalent resource before billing is a practical first step for any newly approved biologic. Prescription management software that tracks drug-to-code pairings can help your billing team stay current as permanent codes are assigned.

Billing guidelines for HCPCS code J3590

Billing J3590 correctly requires more documentation than most specific J-codes. Because the code is unclassified, payers cannot identify the drug from the code alone. Everything below must be addressed before the claim is submitted.

Step 1: Confirm no specific HCPCS code exists

Before using J3590, verify that no product-specific code covers the drug for the date of service. Search a current HCPCS lookup tool by drug name to confirm nothing more specific applies. Billing J3590 when a specific code is available is an incorrect billing practice and triggers denials.

Step 2: Enter the drug name and dosage on the claim

Every J3590 claim must include the drug’s full generic name, brand name, dosage administered, and route of administration. This goes in Box 19 on a CMS-1500 paper claim or in the claim note (NTE) segment on an electronic 837P transaction. Submitting J3590 without a drug name is the single most common denial reason for this code.

Step 3: Report the NDC number

The National Drug Code (NDC) is an 11-digit identifier assigned by the FDA to every drug product. Most commercial payers and many state Medicaid programs require the NDC alongside J3590. The NDC must match the specific product administered, not just the generic molecule.

For electronic claims, the NDC is reported in the drug identification (LIN) segment of the service line (loop 2410). For paper claims, it goes in Box 19 with the qualifier “N4” before the 11-digit number, followed by the unit qualifier (F2 for International Unit, UN for each unit, ML for milliliter, GR for gram).

Step 4: Pair with the correct administration CPT code

J3590 describes the drug only. It does not describe how the drug was given. A matching CPT administration code must appear on the same claim. Common pairings include the ones below, such as the chemotherapy infusion code 96413. Your billing team should confirm with the specific payer which administration codes are accepted alongside J3590.

• 96372: Therapeutic, prophylactic, or diagnostic injection (subcutaneous or intramuscular)
• 96413: Chemotherapy administration, intravenous infusion, up to one hour
• 96365: Intravenous infusion, therapy/prophylaxis/diagnosis, initial hour
• 96366: Each additional hour of IV infusion beyond the first
• 96374: Intravenous push of a single or initial substance/drug (see the IV push billing guide)
• 67028: Intravitreal injection (Used with Avastin off-label for ophthalmology)

Step 5: Obtain and document prior authorization

Most payers require prior authorization (PA) for biologics billed under J3590. PA requirements vary by payer and drug. For HIPAA compliance in medical offices, PA documentation must be retained in the patient record alongside the clinical indication and the prescribing provider’s order. Include the PA reference number on the claim in Box 23 of the CMS-1500 or in the loop 2300 REF segment (qualifier G1) on the 837P.

Documentation requirements for J3590 claims

Medical necessity documentation is non-negotiable for J3590. Because payers cannot verify the drug from the code alone, they rely on chart documentation to confirm the claim is legitimate. Purpose-built clinical documentation software makes these elements easier to capture consistently. Inadequate documentation leads to claim denials and, in audit situations, repayment demands.

Required documentation elements for a J3590 claim:

• Clinical indication: The diagnosis and the clinical reason the biologic was selected over alternatives
• Drug name and strength: Full generic and brand name, concentration, and lot number
• Dosage administered: Actual dose given (not just the prescribed dose), route, and site
• Administration notes: Start and stop time for infusions, infusion rate, any adverse reactions
• Provider order: Signed prescription or standing order from the prescribing clinician
• PA approval: Authorization number, approval date, and approved indication
• Diagnosis codes: Appropriate ICD-10-CM codes supporting medical necessity. Confirm which diagnosis codes your payer considers acceptable for each biologic

Streamline your unclassified biologic billing with Pabau

Pabau's claims management tools help practices attach NDC numbers, track prior authorizations, and submit J3590 claims with the documentation payers require – reducing denials before they happen.

Book a demo

Payer-specific rules for HCPCS code J3590

Payer rules for J3590 vary more than for most HCPCS codes. There is no single national fee schedule rate for unclassified biologics under Medicare Part B because reimbursement depends on the specific drug billed. Practices billing biologics through multiple payer channels need a system to track those differences as part of their broader revenue cycle management.

Medicare Part B

Medicare reimburses physician-administered biologics at Average Sales Price (ASP) plus 6%. Because J3590 has no fixed ASP, Medicare contractors require the drug name and NDC to determine the applicable ASP rate. Reimbursement is looked up via the CMS Physician Fee Schedule and the quarterly ASP drug pricing files. Claims submitted without sufficient drug identification will be denied for lack of required information.

Medicaid (State programs)

State Medicaid programs set their own coverage policies for drugs billed under J3590. North Carolina Medicaid, for example, published specific billing instructions for each newly approved biologic – including Briumvi, Rolvedon, Enjaymo, and Riabni – as those drugs entered the PADP. Practices working with IV therapy EMR software or infusion-heavy workflows need to check each state’s Medicaid coverage bulletin before billing a new biologic under J3590.

Commercial payers

Commercial plans often have the strictest PA requirements for J3590 biologics. Some require step therapy documentation showing the patient tried and failed a lower-cost alternative first.

Blue Cross Blue Shield of Michigan, for instance, issued a provider alert in June 2024 specifically instructing providers to use J3590 for off-label intravitreal Avastin for commercial members. Payer-specific alerts like this are binding – billing a different code under the same plan will result in a denial. For med spa compliance workflows that include physician-administered biologics, maintaining a payer-alert log is a practical audit safeguard.

Common billing mistakes and how to avoid them

J3590 claims have a higher denial rate than specific J-codes because of how much payers depend on biller-submitted information. The most preventable errors follow predictable patterns, and the right medical billing software catches most of them before submission.

• Missing drug name: Submitting J3590 without the drug name in Box 19 or the narrative field is the top denial reason. The claim cannot be processed. Payers return these as unprocessable, not as a formal denial – which means the appeal window may be shorter than expected.
• Wrong NOC code selected: Using J3590 for a conventional small-molecule drug that should be billed as J3490, or using J3590 in a hospital outpatient setting when C9399 applies, generates a code-mismatch denial.
• No administration CPT code: J3590 paired without a CPT administration code will deny for incomplete claim submission. Every drug claim requires a corresponding service code.
• Outdated drug-to-code mapping: Billing J3590 after a permanent HCPCS code has been assigned for the drug results in a denial for incorrect code. This is especially common in the first quarter after CMS issues new J-codes.
• Missing or incorrect NDC: An NDC that does not match the administered product, or a missing NDC on a payer that requires it, causes denial for insufficient information. The NDC must reflect the actual lot dispensed, not just the drug molecule.
• No PA on file: Administering a J3590 biologic without confirmed prior authorization transfers the financial risk to the practice. If EMR software for IV therapy practices or infusion workflows is used, integrating PA tracking directly into the patient workflow prevents this oversight.

Practices that use digital intake and consent forms to capture drug administration details at the point of care reduce transcription errors and ensure the clinical record contains the information needed for claim submission. Structured forms can be built to prompt for NDC, lot number, dosage administered, and administration start and stop times.

Transitioning from J3590 to a permanent HCPCS J-code

The transition from J3590 to a permanent HCPCS code is not automatic. When CMS assigns a dedicated code to a previously unclassified biologic, the new code’s effective date determines when J3590 stops being valid for that drug. Claims submitted after the effective date using J3590 will be denied.

CMS publishes HCPCS quarterly updates in January, April, July, and October. The update files list newly assigned codes, effective dates, and the drugs they cover. Billers should cross-reference these updates against their active J3590 drug list each quarter. Documentation practices that include structured audit trails for code changes help practices demonstrate that transitions were managed correctly in the event of a payer audit.

The transition process typically works as follows:

1. CMS assigns a permanent HCPCS J-code with an effective date in a quarterly update.
2. For dates of service on or after that effective date, only the new permanent code is valid.
3. Claims for dates of service before the effective date may still use J3590 if that was the correct code at the time.
4. Crosswalk the drug name and permanent code into your billing system before the first date of service under the new code.
5. Update any standing orders, charge capture tools, or superbill entries that reference J3590 for that drug.

For practices using functional medicine software that administers a rotating formulary of biologics, setting a workflow reminder for each quarterly HCPCS update cycle is a practical precaution.

Conclusion

HCPCS code J3590 provides a billing path for biologics that have FDA approval but no permanent HCPCS code yet, allowing practices to submit those claims. The challenge is not eligibility – it is documentation. Claims that omit the drug name, NDC, or administration code pairing will deny regardless of whether the drug is covered.

Pabau’s claims management software gives practices the tools to structure J3590 submissions correctly the first time – tracking prior authorizations, capturing NDC details at point of care, and flagging when a permanent HCPCS code has replaced an unclassified biologic code. To see how it fits your billing workflow, book a demo.

Continue your research

Need to manage physician-administered drug billing across multiple payers? Pabau claims management software helps practices submit clean claims with the documentation payers require for unclassified biologics.

Running an infusion or IV therapy practice? IV therapy EMR software covers the end-to-end workflow from intake through drug administration documentation and billing.

Want to reduce documentation errors at the point of care? Pabau’s digital forms can be configured to capture NDC numbers, lot numbers, dosage, and administration times directly from your clinical team.

Frequently Asked Questions